Editor - BiopharmaJournal.com

545 POSTS 0 COMMENTS

Wall Street is my passion and I love pursuing it but with a pen ! After my Master's in Journalism, I joined Bio Pharma Journal as a freelance writer and was soon promoted to an associate editor position.

Chimerix Inc (NASDAQ: CMRX) Receives $25.3 Million Procurement Contract For TEMBEXA

Kate Hudson - July 4, 2022 0

Regulus Therapeutics Inc (NASDAQ: RGLS) Pleased after FDA Approved its Orphan...

Kate Hudson - July 1, 2022 0

Tapping Recession-Proof Stocks to Fight the Bear (SNPS, KEGS, SAM, ABT,...

Kate Hudson - June 23, 2022 0

Two Stocks for the Unique Boom Opportunity in the Fashion Space...

Kate Hudson - June 9, 2022 0

Ocugen Inc (NASDAQ: OCGN) Recently Issued an Update to Its Shareholders...

Kate Hudson - June 1, 2022 0

The Green Infrastructure Stock Boom Waits Around the Corner (LXU, ECOX,...

Kate Hudson - May 10, 2022 0

Obseva SA (NASDAQ: OBSV) Receives Another Positive Review From the CHMP

Kate Hudson - May 6, 2022 0

Protagonist Therapeutics Inc (NASDAQ: PTGX) Receives Positive Results From the Phase...

Kate Hudson - May 5, 2022 0

Activist Investing LLC Buys Common Stock From Titan Pharmaceuticals, Inc. (NASDAQ:...

Kate Hudson - May 5, 2022 0

Applied Molecular Transport Inc. (NASDAQ: AMTI) Announces Positive Results For AMT-101...

Kate Hudson - May 4, 2022 0

12 3...55 Page 1 of 55

CymaBay Therapeutics Inc (NASDAQ: CBAY) Announces Promising Seladelpar Data In Treatment...

Gavins Felicity - July 5, 2022 0

CymaBay Therapeutics Inc (NASDAQ: CBAY) has announced the presentation of promising seladelpar findings in primary biliary cholangitis (PBC) patients at The International Liver Congress...